Health Technology Assessment: Choices That Must Be Made for Reviewing the Evidence - The Cyprus Perspective
A Health Technology Assessment agency should make a choice whether to review the evidence produced elsewhere or whether evidence is to be produced within the agency and then used to reach a decision. The small size of Cyprus with limited resources should be considered in order to draw the most appropriate conclusion, with regard to the evidence production by the newly established agency. This project analyzes at which point in time Cyprus makes the decision to integrate new high cost medicines into the Formulary of Hospital Drugs, in relation to the time of publication of decisions, taken by the Health Technology Assessment agencies in England and Wales, Scotland and Ireland, for the inclusion of the same medicines and for the same indication, in their national health systems. The review of evidence produced elsewhere would be feasible for Cyprus, as opposition to the production of evidence being undertaken by the new agency, in the case where the other agencies would have already produced evidence before the Cyprus Authority starts reviewing them.
Health Technology Assessment, Reviewing of Evidence, Cyprus
Akehurst RL, Abadie E, Renaudin N, Sarkozy F. Variation in Health Technology Assessment and Reimbursement Processes in Europe, Value Heal. 2017; 20 (1): 67–76.
Hailey D. Involvement of Patients in Health Technology Assessment: Further Perspectives for Informing Decision-Makers. Hosp Pract Res, 2017; 2 (3): 58–62.
Facey K, Henshall C, Sampietro-Colom L. Improving effectiveness and efficiency of evidence production for Health Technology Assessment. Int J Technol Assess Health Care, 2015; 31 (4): 201–6.
Chalkidou K, Marten R, Cutler D, Culyer T, Smith R, Teerawattananon Y, et al. Health technology assessment in universal health coverage. Lancet, 2013; 382 (9910): e48-9.
Youngkong S. Application of HTA research on policy decision-making. J Med Assoc Thail, 2014; 97 (Suppl 5): 119–26.
Lysdahl KB, Mozygemba K, Burns J, Brönneke JB, Chilcott JB, Ward S, et al. Comprehensive assessment of complex technologies: integrating various aspects in health technology assessment. Int J Technol Assess Health Care, 2017; 33 (5): 570–6.
Cairns J, Maynou-Pujolras L, Miners A. Organisational issues for building Health Technology Assessment (HTA) capacity in Cyprus Report. 2014.
Löblová O. What has health technology assessment ever done for us? J Health Serv Res Policy [online]. 2017 Sep 19; 23 (2): 134–6. Available from: http: //journals.sagepub.com.
Oortwijn W, Broos P, Vondeling H, Banta D, Todorova L. Mapping of health technology assessment in selected countries. Int J Technol Assess Health Care, 2013; 29 (4): 424–34.
SMC. Scotland: SMC [online]. 2018 [cited 2018 Nov 14]. Available from: www.scottishmedicines.org.uk.
Kolasa K, Wasiak R. Health technology assessment in Poland and Scotland: Comparison of process and decisions. Int J Technol Assess Health Care, 2012; 28 (1): 70–6.
Rawlins M. National Institute for Clinical Excellence: NICE works. J R Soc Med. 2015; 108 (6): 211–9.
Raftery J, Powell J. Health Technology Assessment in the UK. Lancet, 2013; 382 (9900): 1278–85.
NCPE. National Cetre for Pharmacoeconomics NCPE Irland [online]. 2019 [cited 2019 Feb 6]. Available from: http: //www.ncpe.ie/publications.
European Commission. European Commission: Impact Assessement-Strengthening of the EU Cooperation on HTA [online]. 2018. Available from: https: //ec.europa.eu/health/sites/health.
Banta David H. Dissemination of Health technology assessment. Cham, Springer International Publishing, 2015, 147-156 p.